Cover Image
市場調查報告書

癌症基因治療的全球市場:各治療法 (遺傳基因誘導免疫治療,溶瘤病毒療法,基因轉移) - 市場機會分析與產業預測

Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer) - Global Opportunity Analysis and Industry Forecast, 2017-2023

出版商 Allied Market Research 商品編碼 586563
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症基因治療的全球市場:各治療法 (遺傳基因誘導免疫治療,溶瘤病毒療法,基因轉移) - 市場機會分析與產業預測 Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer) - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日期: 2017年10月01日 內容資訊: 英文 150 Pages
簡介

本報告提供全球致癌基因治療的市場相關分析,技術概要和市場基本結構,主要的推動及阻礙市場的要素,市場規模預測 (今後7年份),各治療法、各地區的詳細趨勢,主要企業簡介等調查。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 分析的要點
    • 主要的投資財源
    • 主要的成功策略
  • 法規、醫療費償付方案
  • 波特的五力分析

第4章 癌症基因治療的市場:各治療法

  • 概要
    • 市場規模與其預測
  • 溶瘤病毒療法
    • 市場主要趨勢
    • 成長要素與市場機會
    • 市場規模與其預測
    • 腺病毒
    • 慢病毒
    • 反轉錄病毒
    • 腺結合病毒
    • 單純皰疹病毒
    • Alpha病毒
    • 牛痘病毒
    • 猿猴病毒
    • 其他
  • 基因轉移
    • 裸/質粒載體
    • 電穿孔 (電力穿孔法)
    • Sonoporation
    • Magnetofection
    • 基因槍
  • 遺傳基因誘導免疫治療
    • 細胞激素遺傳基因的傳遞
    • 抗原遺傳基因的傳遞

第5章 癌症基因治療的市場:各地區

  • 概要
  • 北美
    • 市場主要趨勢
    • 成長要素與市場機會
    • 市場規模與其預測:美國,加拿大,墨西哥
    • 各治療法的市場規模
  • 歐洲
    • 市場規模與其預測:德國,法國,英國,義大利,西班牙等
  • 亞太地區
    • 市場規模與其預測:日本,中國,澳洲,義大利,西班牙等
  • 南美、中東、非洲 (LAMEA)
    • 市場規模與其預測:巴西,土耳其,沙烏地阿拉伯,南非等

第6章 企業簡介

  • ADAPTIMMUNE
    • 事業結構
    • 業績
    • 主要企業策略、行動
  • GLAXOSMITHKLINE
  • BLUEBIRD BIO, INC.
  • MERCK
  • CELGENE
  • SHANGHAI SUNWAY BIOTECH
  • BIOCANCELL
  • SHENZHEN SIBIONO GENETECH
  • SYNERGENE THERAPEUTICS
  • ONCOGENEX PHARMACEUTICALS
目錄
Product Code: LI 02605

Gene therapy is an experimental technique that encompasses the replacement of mutated genes with healthy genes. During the treatment of cancer, the genes are replaced to fight against carcinogenic tumor cells. Gene therapy is considered to be an effective treatment for chronic diseases as they cause minimum side effects with maximum efficacy. The global cancer gene therapy market was valued at $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023.

The rise in prevalence of cancer, benefits of cancer gene therapy over conventional cancer therapies, and the advancement in this field are the major factors that drive the market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in biotechnological funding encourage the R&D activities for cancer gene therapy and thus fuel the growth of the cancer gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to restrain the market growth.

The global cancer gene therapy market is segmented based on therapy, end user, and geography. Based on therapy, it is categorized into gene induced immunotherapy (delivery of cytokines gene and delivery of tumor antigen gene), oncolytic virotherapy (adenovirus, lentivirus, retro virus, adeno associated virus, herpes simplex virus, alpha virus, vaccinia virus, simian virus, and others), and gene transfer (naked plasmid vector, electroporation, sonoportion, magnetofection, and gene gun). Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
  • In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY PLAYERS PROFILED

  • Adaptimmune
  • GlaxoSmithKline
  • Bluebird bio, Inc.
  • Merck
  • Celgene
  • Shanghai Sunway Biotech
  • BioCancell
  • Shenzhen SiBiono GeneTech
  • SynerGene Therapeutics
  • OncoGenex Pharmaceuticals

KEY MARKET SEGMENTS

By Therapy

  • Gene Induced Immunotherapy
  • Delivery of Cytokines Gene
  • Delivery of Tumor Antigen Gene
  • Oncolytic Virotherapy
  • Adenovirus
  • Lentivirus
  • Retro Virus
  • Adeno Associated Virus
  • Herpes Simplex Virus
  • Alpha Virus
  • Vaccinia Virus
  • Simian Virus
  • Others
  • Gene Transfer
  • Naked/Plasmid Vectors
  • Electroporation
  • Sonoportion
  • Magnetofection
  • Gene Gun

By End User

  • Hospitals
  • Diagnostics Centers
  • Research Institutes

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Republic of South Africa
  • Saudi Arabia
  • Rest of LAMEA

The other players of the cancer gene therapy market include (companies not profiled in the report):

  • Cell Genesys
  • Advantagene
  • GenVec
  • BioCancell
  • Celgene and Epeius Biotechnologies
  • Introgen Therapeutics
  • Ziopharm Oncology
  • Shenzhen SiBiono GeneTech
  • Genelux Corporation
  • Altor Bioscience

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. REGULATION AND REIMBURSEMENT SCENARIO
  • 3.4. PORTERS FIVE FORCES ANALYSIS
    • 3.4.1. MARKET DYNAMICS
    • 3.4.2. Drivers
    • 3.4.3. Restraints
    • 3.4.4. Opportunities

CHAPTER 4 CANCER GENE THERAPY MARKET, BY THERAPY

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. ONCOLYTIC VIROTHERAPY
    • 4.2.1. Key market trends
    • 4.2.2. Growth factors and opportunities
    • 4.2.3. Market size and forecast
    • 4.2.4. Adenovirus
    • 4.2.5. Lentivirus
    • 4.2.6. Retro virus
    • 4.2.7. Adeno associated virus
    • 4.2.8. Herpes simplex virus
    • 4.2.9. Alpha Virus
    • 4.2.10. Vaccinia Virus
    • 4.2.11. Simian Virus
    • 4.2.12. Others
  • 4.3. GENE TRANSFER
    • 4.3.1. Key market trends
    • 4.3.2. Growth factors and opportunities
    • 4.3.3. Market size and forecast
    • 4.3.4. Naked plasmid vector
    • 4.3.5. Electroporation
    • 4.3.6. Sonoportion
    • 4.3.7. Magnetofection
    • 4.3.8. Gene Gun
  • 4.4. GENE-INDUCED IMMUNOTHERAPY
    • 4.4.1. Key market trends
    • 4.4.2. Growth factors and opportunities
    • 4.4.3. Market size and forecast
    • 4.4.4. Delivery of cytokines gene
    • 4.4.5. Delivery of tumor antigen gene

CHAPTER 5 CANCER GENE THERAPY MARKET, BY GEOGRAPHY

  • 5.1. OVERVIEW
  • 5.2. NORTH AMERICA
    • 5.2.1. Key market trends
    • 5.2.2. Key growth factors and opportunities
    • 5.2.3. Market size and forecast
      • 5.2.3.1. U.S. market size and forecast
      • 5.2.3.2. Canada market size and forecast
      • 5.2.3.3. Mexico market size and forecast
    • 5.2.4. North America Cancer gene therapy Market by Therapy
  • 5.3. EUROPE
    • 5.3.1. Key market trends
    • 5.3.2. Key growth factors and opportunities
    • 5.3.3. Market size and forecast
      • 5.3.3.1. Germany market size and forecast
      • 5.3.3.2. France market size and forecast
      • 5.3.3.3. UK market size and forecast
      • 5.3.3.4. Italy market size and forecast
      • 5.3.3.5. Spain market size and forecast
      • 5.3.3.6. Rest of Europe market size and forecast
    • 5.3.4. Europe Cancer gene therapy Market by Therapy
  • 5.4. ASIA-PACIFIC
    • 5.4.1. Key market trends
    • 5.4.2. Key growth factors and opportunities
    • 5.4.3. Market size and forecast
      • 5.4.3.1. Japan market size and forecast
      • 5.4.3.2. China market size and forecast
      • 5.4.3.3. Australia market size and forecast
      • 5.4.3.4. India market size and forecast
      • 5.4.3.5. South Korea market size and forecast
      • 5.4.3.6. Taiwan market size and forecast
      • 5.4.3.7. Rest of Asia-Pacific market size and forecast
    • 5.4.4. Asia-Pacific Cancer gene therapy Market by Therapy
  • 5.5. LAMEA
    • 5.5.1. Key market trends
    • 5.5.2. Key growth factors and opportunities
    • 5.5.3. Market size and forecast
      • 5.5.3.1. Brazil market size and forecast
      • 5.5.3.2. Turkey market size and forecast
      • 5.5.3.3. Saudi Arabia market size and forecast
      • 5.5.3.4. South Africa market size and forecast
      • 5.5.3.5. Rest of LAMEA market size and forecast
    • 5.5.4. LAMEA Cancer gene therapy Market by Therapy

CHAPTER 6 COMPANY PROFILES

  • 6.1. ADAPTIMMUNE
    • 6.1.1. Operating business segments
    • 6.1.2. Business performance
    • 6.1.3. Key strategic moves and developments
  • 6.2. GLAXOSMITHKLINE
    • 6.2.1. Operating business segments
    • 6.2.2. Business performance
    • 6.2.3. Key strategic moves and developments
  • 6.3. BLUEBIRD BIO, INC.
    • 6.3.1. Operating business segments
    • 6.3.2. Business performance
    • 6.3.3. Key strategic moves and developments
  • 6.4. MERCK
    • 6.4.1. Operating business segments
    • 6.4.2. Business performance
    • 6.4.3. Key strategic moves and developments
  • 6.5. CELGENE
    • 6.5.1. Operating business segments
    • 6.5.2. Business performance
    • 6.5.3. Key strategic moves and developments
  • 6.6. SHANGHAI SUNWAY BIOTECH
    • 6.6.1. Operating business segments
    • 6.6.2. Business performance
    • 6.6.3. Key strategic moves and developments
  • 6.7. BIOCANCELL
    • 6.7.1. Operating business segments
    • 6.7.2. Business performance
    • 6.7.3. Key strategic moves and developments
  • 6.8. SHENZHEN SIBIONO GENETECH
    • 6.8.1. Operating business segments
    • 6.8.2. Business performance
    • 6.8.3. Key strategic moves and developments
  • 6.9. SYNERGENE THERAPEUTICS
    • 6.9.1. Operating business segments
    • 6.9.2. Business performance
    • 6.9.3. Key strategic moves and developments
  • 6.10. ONCOGENEX PHARMACEUTICALS
    • 6.10.1. Operating business segments
    • 6.10.2. Business performance
    • 6.10.3. Key strategic moves and developments

List of Tables

  • TABLE 1. GLOBAL CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
  • TABLE 2. CANCER GENE THERAPY MARKET FOR GENE INDUCED IMMUNOTHERAPY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 3. CANCER GENE THERAPY MARKET FOR ONCOLYTIC VIROTHERAPY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 4. CANCER GENE THERAPY MARKET FOR GENE TRANSFER, BY REGION, 2016-2023 ($MILLION)
  • TABLE 5. CANCER GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 6. NORTH AMERICA CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 7. NORTH AMERICA CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
  • TABLE 8. EUROPE CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 9. EUROPE CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
  • TABLE 10. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 11. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
  • TABLE 12. LAMEA CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 13. LAMEA CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
  • TABLE 14. ADAPTIMMUNE: COMPANY SNAPSHOT
  • TABLE 15. ADAPTIMMUNE: OPERATING SEGMENTS
  • TABLE 16. GLAXOSMITHKLINE: COMPANY SNAPSHOT
  • TABLE 17. GLAXOSMITHKLINE: OPERATING SEGMENTS
  • TABLE 18. BLUEBIRD: COMPANY SNAPSHOT
  • TABLE 19. BLUEBIRD: OPERATING SEGMENTS
  • TABLE 20. MERCK: COMPANY SNAPSHOT
  • TABLE 21. MERCK: OPERATING SEGMENTS
  • TABLE 22. CELGENE: COMPANY SNAPSHOT
  • TABLE 23. CELGENE: OPERATING SEGMENTS
  • TABLE 24. SHANGHAI SUNWAY BIOTECH: COMPANY SNAPSHOT
  • TABLE 25. SHANGHAI SUNWAY BIOTECH: OPERATING SEGMENTS
  • TABLE 26. BIOCANCELL: COMPANY SNAPSHOT
  • TABLE 27. BIOCANCELL: OPERATING SEGMENTS
  • TABLE 28. SHENZHEN SIBIONO GENETECH: COMPANY SNAPSHOT
  • TABLE 29. SHENZHEN SIBIONO GENETECH: OPERATING SEGMENTS
  • TABLE 30. SYNERGENE THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 31. SYNERGENE THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 32. ONCOGENEX PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 33. ONCOGENEX PHARMACEUTICALS: OPERATING SEGMENTS

List of Figures

  • FIGURE 1. SEGMENTATION OF GLOBAL CANCER GENE THERAPY MARKET
  • FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL CANCER GENE THERAPY MARKET 2016
  • FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
  • FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE (2014-2016)
  • FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY (2014-2016)
  • FIGURE 6. BARGAINING POWER OF BUYERS
  • FIGURE 7. BARGAINING POWER OF SUPPLIERS
  • FIGURE 8. THREAT OF NEW ENTRANTS
  • FIGURE 9. THREAT OF SUBSTITUTION
  • FIGURE 10. COMPETITIVE RIVALRY
  • FIGURE 11. RESTRAINTS AND DRIVERS: GLOBAL CANCER GENE THERAPY MARKET
  • FIGURE 12. GLOBAL CANCER GENE THERAPY MARKET: SEGMENTATION BY TYPE
  • FIGURE 13. U.S. CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 14. MEXICO CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 15. CANADA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 16. UK CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 17. FRANCE CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 18. GERMANY CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 19. REST OF EUROPE CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 20. INDIA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 21. JAPAN CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 22. CHINA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 23. REST OF ASIA-PACIFIC CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 24. BRAZIL CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 25. SOUTH AFRICA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 26. SAUDI ARABIA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
  • FIGURE 27. REST OF LAMEA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
Back to Top